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Abstract 
Hormonal regulation of phospholipase D (PLD) was studied in isolated rat liver plasma membranes. Purinergic agents and a 
submaximal concentration f guanosine 5'-0-(3-thiotriphosphate) (GTPTS), a non-hydrolyzable analog of GTP, synergistically stimulate 
phosphatidylethanol f rmation, a measure of PLD activity. The rank order of efficacy for stimulation of PLD activity in the presence of 
0.2 /zM GTPy S was /3, y-methylene-ATP > adenosine 5'-0-(3-thiotriphosphate) = ATP = ADP = 2-methylthio-ATP > a,/3-methylene- 
ATP = UTP. This pattern of activation does not conform to the series at known P2 receptors. GTPTS stimulated PLD activity in a 
dose-dependent manner, and the GTPTS dose-response curve for phosphatidylethanol f rmation was shifted to the left by an analog of 
ATP. Activation of PLD by purinergic agents in the presence of GTPyS supports the involvement of a purinergic receptor of the P2 class 
and a GTP-binding protein. Purinergic agents competitively inhibited [35S]adenosine 5'-0-(3-thiotriphosphate) binding to plasma 
membranes in the rank order adenosine 5'-0'(3-thiotriphosphate) > ATP > a,/3-methylene-ATP = UTP >>/3, y-methylene-ATP = ADP. 
Stimulation of phosphoinositide phospholipase C (PI-PLC) by purinergic agents, as measured by release of radioactivity from 
endogenously myo[3H]inositol-labeled plasma membranes, occurred in the order re, /3-methylene-ATP >> 2-methylthio-ATP. /3,y-meth- 
ylene-ATP had little effect on PI-PLC activity. Different dose-response relationships for agonist-stimulation f PI-PLC and PLD indicate 
that activation of PI-PLC is not involved in stimulation of PLD in rat liver plasma membranes, and suggest that purinergic activation of 
PLD occurs via a pathway involving a G protein and a heretofore uncharacterized P2 receptor. 
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1. Introduction 
Hydrolysis of phosphatidylcholine by phospholipase D 
(PLD) leads to the formation of phosphatidic acid, a 
putative signalling molecule [1,2]. In the presence of 
ethanol, or other primary alcohols, PLD catalyzes a trans- 
phosphatidylation reaction which produces phosphatidylal- 
cohol at the expense of phosphatidic acid production. 
Phosphatidylethanol (PEth) formation, in the presence of 
ethanol, is therefore a specific marker for PLD activity. 
Hormones and growth factors stimulate PLD activity in 
Abbreviations: PEth, phosphatidylethanol; PA, phosphatidic a id; PC, 
phosphatidylcholine; PI, phosphoinositide; GTP~S, guanosine 5'-0-(3- 
thiotriphosphate); G protein, GTP-binding protein; PLD, phospholipase 
D; PLC, phospholipase C; AMP-PCP, /3, T-methylene-ATP; AMP-CPP, 
a, fl-methylene-ATP; 2MeSATP, 2-methylthio-ATP; ATPTS, adenosine 
5'-0-(3-thiotriphosphate); PMA,phorbol 12-myristate 13-acetate. 
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numerous tissues and cell types [1,2]. For example, ago- 
nists that activate seven transmembrane-spanning receptors 
stimulate PLD activity in rat hepatocytes [3-5], neutrophils 
and HL60 cells [6-9], MC3T3-E1 osteoblast-like cells 
[10], ratl and Swiss 3T3 fibroblasts [11-13], smooth mus- 
cle cells [14,15], and endothelial cells [16-19] (see Ref. [2] 
for a comprehensive list). In some cases, enhancement of
agonist-stimulated PLD activity by GTP, or its non-hydro- 
lyzable analog GTPyS, in permeabilized cells has impli- 
cated the involvement of G proteins [4,10,16]. Whereas 
GTP,/S stimulation of PLD activity can be reconstituted 
when fractionated plasma membranes and cytosol of some 
cell types are combined [20], few reports exist of agonist- 
and GTPTS-stimulated PLD activity in isolated plasma 
membranes [4,21]. 
We have previously shown that plasma membranes 
derived from rat liver respond to ATP and ADP in the 
presence of GTP,/S with activation of PLD, and have 
obtained evidence implicating P2-purinergic receptors. A1- 
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though it is not clear if stimulation of PLD by purinergic 
agonists occurs directly by activation of a PLD-linked G 
protein, these experiments demonstrate hat all the compo- 
nents necessary for agonist-stimulated PLD activity are 
present in the plasma merabranes of rat liver. 
A number of ATP-binding cell-surface receptors have 
been defined by functional, pharmacological and molecular 
genetic approaches [22-26]. Among the predominant sub- 
types, the P2x receptor is 'believed to be a ligand-gated ion 
channel [26], and the Pzz receptor activates a non-selective 
pore by an unknown mechanism, and also stimulates a
PLD activity [26,27], whereas the P2u and P2v receptors 
activate PLC through an action mediated by the c~-or 
fly-subunits of certain heterotrimeric G proteins [28]. Acti- 
vation of P2z receptors occurs by binding of ATP 4-, and is 
distinguished by activation in the potency order ATP >> 
ADP, mainly in macrophages and mast cells. The Pzx- 
purinergic receptor is found predominantly in neuronal 
tissue and is activated in the potency order AMP-CPP = 
AMP-PCP > ATP = ADF' > 2MeSATP; the P2Y puriner- 
gic receptor is activated in the potency order 2MeSATP >> 
ATP = ADP > AMP-CPP > AMP-PCP; and the P2u re- 
ceptor is activated in the potency order UTP = ATP > 
ATPyS > 2MeSATP > AMP-PCP = ADP = AMP-CPP. 
P2u and Pzv receptors have been identified in rat liver by 
detection of Pzu mRNA and the responses to subtype- 
specific agonists [25,29]. 
Activation of PI-PLC by seven transmembrane-span- 
ning receptors linked to G proteins timulates the hydroly- 
sis of PIP 2 to IP 3, a mobilizer of intracellular calcium, and 
DAG, an activator of PKC. Activation of PLD by PKC is 
widespread, and may explain receptor-mediated and 
GTPT S-stimulated PLD activity in whole cells through the 
sequential activation of PLC and PKC [1,2]. Although 
PKC is customarily thollght to exert its effects through 
protein phosphorylation, there is evidence in CCL39 fi- 
broblasts that activation ,3f PLD by PKC may not require 
protein phosphorylation 1130]. However, it is also possible 
that GTPyS-stimulated PLD activity may be independent 
of PI-PLC and PKC, and may involve activation of PLD 
by a specific G protein. Recently, members of the Rho and 
ARF families of Ras-rel~Lted low molecular weight (small) 
G proteins have been implicated in GTPyS-stimulated 
PLD activity [31-34]. However, it is not clear if receptor- 
activated PLD involves these small G proteins. The present 
studies further characterize the activation of membrane-as- 
sociated PLD of rat liver by purinergic agonists, and 
provide evidence against he involvement of PI-PLC and 
PKC. 
chemicals and all other nucleotide were from Sigma. 
myo[3H]Inositol was obtained from Amersham, and 
[35S]ATPTS was from NEN. Bisindolylmaleimide was 
from Calbichem. 
2.2. PLD assay 
PLD activity was determined as previously described by 
measuring the accumulation of PEth mass [3,32]. The final 
assay volume was 0.2 ml and contained 0.35 mg of 
membrane protein, 50 mM Hepes (pH 7.5), 10 mM MgC12 
1 mM EGTA, 150 mM ethanol, and the indicated concen- 
tration of GTPTS. Experiments concerning activation of 
purinergic receptors additionally contained 0.8 mM CaCI 2 
(an estimated free Ca 2+ concentration of 200 nM was 
determined by the COMICS program), the indicated con- 
centration of ATP, ADP, 2MeSATP, AMP-CPP, AMP- 
PCP, ATPyS, and UTP, and other additions as described. 
Incubation temperature was 37°C for the indicated time. 
2.3. Plasma membrane preparation 
Plasma membranes from the livers of male Sprague- 
Dawley rats were prepared as described by Prpic et al. 
[35], and stored at -70°C. Alternatively, rats were injected 
interperitoneally with 500 /xCi myo[3H]inositol (17.1 
Ci/nmol; 1 mCi/ml) 18 h before harvesting plasma mem- 
branes [36]. Radioactive label was incorporated > 95% 
into PI with a minor incorporation i to PIP and PIP 2. The 
final membrane preparations contained between 10 000 and 
25 000 cpm/mg of protein. 
2.4. [35S]ATPTS binding 
Binding experiments were performed at room tempera- 
ture in a final volume of 0.1 ml for the indicated times for 
the time course study, and for 30 min in the competition 
studies [37]. Assays were carried out in Buffer A (50 mM 
Hepes (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1 mM 
MgC1 z and 200 ~M sodium orthovanadate), with 1 nM 
[35S]ATPyS (1193 Ci/nmol), and were initiated by the 
addition of 75 /xg membrane protein. Reactions were 
terminated by addition of 3 ml ice-cold Buffer A, followed 
by vacuum-filtration over Whatman GF/F  filters, and 
subsequently washed 3 times in 3 ml ice-cold Buffer A. 
Filters were soaked in Beckman ReadySafe overnight and 
filter-bound radioactivity determined by liquid scintillation 
counting. Results were normalized to radioactivity in the 
absence of competitor, which was taken as 100% binding. 
2. Experimental procedures 
2.1. Materials 
AMP-PCP, ATPyS and GTPTS were purchased from 
Boehringer Mannheim, 2MeSATP was from Research Bio- 
2.5. Measurement of PI-PLC activity 
Membranes (350 /zg) from myo[3H]inositol-injected 
rats were incubated in a final volume of 0.2 ml in 50 mM 
Hepes (pH 7.5), 10 mM MgC12, 1.95 mM CaCI 2, 2 mM 
EGTA, 2 /xM GTPTS, and the indicated concentration f
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agonist at 37°C for 10 min [36]. The free Ca 2÷ concentra- 
tion was calculated to be 1.3 /zM by the COMICS pro- 
gram. Reactions were terminated with 200 tzl of ice-cold 
10% trichloroacetic a id and 100 /zl of 1% bovine serum 
albumin. Tubes were allowed to stand on ice for 10 min 
after vortex mixing, and were subsequently centrifuged at 
7000 × g for 3 min. A 0.4-ml portion of the superuatant 
was pipetted into a scintillation vial, 10 ml of ReadySafe 
added, and soluble radioactivity products determined by 
liquid scintillation counting. The radioactivity at zero time, 
usually about 100 cpm, was subtracted from each data 
point to determine stimulated release of radioactivity. Re- 
lease of cpm was due to the production of [3H]inositol 
phosphates [36] and was Ca2÷-dependent, consistent with a 
PLC-mediated process. We did not discriminate among 
[3H]inositol phosphates due to the low level of radioactiv- 
ity released. 
2.6. Data analysis and presentation 
Determination of ECs0 and IC50 values was performed 
using GraphPad InPlot software. Data represent means + 
standard error of three or more experiments performed in 
duplicate, unless otherwise indicated. 
3. Results 
3.1. Stimulation of PLD by ATP analogs and GTPTS 
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Fig. l. Synergistic activation of PLD by GTP',/S and AMP-PCP. (A) 
Plasma membranes were incubated with GTPyS (0.2 p.M) and AMP-PCP 
(1 mM) as indicated for 20 min at 37°C, and PEth formation determined 
as described in Section 2. Values plotted are the percent increase in PEth 
above that in the absence of any stimuli, which corresponds to 0.4 _+ 0.1 
/zg PEth/mg membrane protein/20 min (n = 10). (B) Time-dependent 
formation of PEth by 0.2 /xM GTPyS without (0) and with (0 )  1 mM 
AMP-PCP. Data are representative of three experiments performed in 
duplicate. 
Stimulation of PLD activity in rat liver plasma mem- 
branes by GTPyS has been previously shown [3,4]. Fur- 
thermore, ATP or ADP and a submaximal concentration f 
GTPyS synergistically activate PLD, suggesting the in- 
volvement of purinergic receptors [4]. We extended these 
findings using the ATP analog AMP-PCP, which has 
greater stability than ATP and is unlikely to mediate its 
effects by a phosphotransferase reaction or by competing 
with GTPyS hydrolysis. Incubation of plasma membranes 
with either a submaximal concentration of GTPyS (0.2 
/zM) or AMP-PCP (1 mM) increased PEth formation by 
100 + 25% and 185 _ 31%, respectively, over the level in 
unstimulated plasma membranes (Fig. 1A). However, 
AMP-PCP in the presence of GTPyS caused a greater 
stimulation of the activity than either agent alone, to 
452 ___ 45% over basal (Fig. 1A), suggesting the functional 
interaction of a purinergic receptor, a G protein and a 
membrane-associated PLD. Time course studies indicated 
an increase in PLD activity induced by 0.2 /xM GTPyS 
(Fig. 1B); PEth formation was 2.4-fold of that in the 
absence of any stimuli after 40 min. The rate and extent of 
PEth formation was greatly enhanced by the further addi- 
tion of AMP-PCP (Fig. IB). 
Dose-dependent formation of PA by GTPyS has been 
previously demonstrated in rat liver plasma membranes [4], 
but the effects of purinergic agonists on this response have 
not been tested. Fig. 2 shows that GTPyS stimulated PLD 
activity, as measured by PEth formation, with an ECs0 of 
3.2 ~M and a maximal effect at 20 ~M, which is in 
agreement with GTPy S-stimulated PA formation [4]. Addi- 
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Fig. 2. Dose-dependent stimulation of PLD by GTPTS is sensitive to 
AMP-PCP. Plasma membranes were stimulated with the indicated con- 
centration of GTPTS for 10 min without (0) or with (0 )  1 mM 
AMP-PCP. Values represent the percent of the maximal response for each 
of three experiments performed in duplicate, and correspond to 1.5 + 0.3 
mg PEth formed/rag membrane protein/10 min. 
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tion of AMP-PCP shifted the ECs0 to 0.11 ~M and the 
maximum effect was achieved at 2 p~M GTPTS. The large 
shift of the GTPTS dose-response curve to the left is 
indicative of a G protein-coupled reaction. 
To further characterize the role of purinergic receptors 
in the activation of PLD, dose-response curves were gener- 
ated using ATP, several ATP analogs, ADP and UTP. PLD 
was activated by all these agents to varying extents in the 
presence of 0.2 /zM GTP~/S (Fig. 3). The efficacy order 
was AMP-PCP > ATPTS = ATP = ADP = 2MeSATP > 
AMP-CPP = UTP (Fig. 3). Under these conditions, 1 mM 
AMP-PCP plus 0.2 /xM GTPTS produced a similar re- 
sponse to 20 /zM GTPTS, which is the maximal response. 
These ligands had much less effect on PLD activity in the 
absence of GTPTS (Fig. 1 and Fig. 2 and data not shown). 
Accurate measurement of ECs0 values was complicated by 
steep dose-response curves, but were estimated within the 
range of 100 to 300 /zM. The efficacy of purinergic 
agonists for activation of PLD given above does not 
conform to the order for interaction with known purinergic 
receptors activating other responses. Therefore, we ana- 
lyzed the binding of purinergic agents to rat liver plasma 
membranes to further define the receptor. 
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Fig. 3. Dose-dependent stimulation of PLD by purinergic agents. Plasma 
membranes were incubated with the indicated concentration f purinergic 
agents for 10 min in the presence of 0.2 p~M GTPTS, and PEtb formation 
was determined. Maximal PEth formation was determined with 20 p~M 
GTPTS for each dose-response curve. (A) Stimulation of PLD by AMP- 
PCP (0), ATPTS (0 ) ,  ATP (v )  and UTP (• ) ;  and (B) AMF-PCP (0), 
ADP (O), 2MeSATP ( v ) and AMP-CPP ( • ). The response to AMP-PCP 
is shown in both figures for comparative purposes. 
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Fig. 4. Time-dependent binding of [35S]ATPTS. Plasma membranes were 
incubated with 1 nM [35S]ATPTS for the indicated times at room 
temperature in the absence (0) or presence (1~) of 2 mM ATP to 
determine total-and non-specific binding, respectively. Specific binding 
( • ) was determined by subtracting non-specific binding from total-bind- 
ing. The data in Figs. 4 and 5 are the means + S.E.M. of three or more 
experiments performed in triplicate. Error bars have been omitted for 
clarity. 
3.2. [35S]ATPTS binding to membranes 
[3sS]ATPTS bound to rat liver plasma membranes in a 
time-dependent manner, and maximal specific binding was 
attained after 20 min (Fig. 4). Non-specific binding was 
measured in the presence of 2 mM ATP and represented 
18% of total binding at 20 min. Binding competition 
curves were generated using ATP, several ATP analogs, 
ADP and UTP. The highest concentrations of the different 
ligands were about equally effective at competing with 
[35S]ATPTS for binding to plasma membranes (Fig. 5); an 
exception was the highest ested concentration of ATPy S 
(3 mM) which allowed greater retention of bound 
[ 35 S]ATPT S. Competition for [35 S]ATPT S binding sites by 
ligands was in the rank order ATPT S > ATP > AMP-CPP 
= UTP >> AMP-PCP = ADP (Table 1 and Fig. 5). In 
addition, ATPyS, ATP and AMP-PCP had low affinity 
sites representing 23, 35% and 73% of the total number of 
sites, respectively (Table 1). Inhibition of [35S]ATPTS 
binding by AMP-CPP, UTP and ADP fitted to a one-site 
model. The low affinity site for ATPTS (IC50 = 13 /xM) 
was also within the range of the affinities for the other 
ligands, whereas the low affinity site for ATP had an ICs0 
value of 900/zM, and that for AMP-PCP was greater than 
1 mM (Table 1). Adenosine, the physiologic agonist for P1 
receptors, did not compete for [35S]ATPTS binding at a 
concentration of 3 mM (data not shown), indicating the 
measurement of binding to P2 purinergic receptors by this 
protocol. However, the competition data do not conform to 
the affinity profile of known P2 purinergic receptor sub- 
types. 
3.3. Functional relationship between PI-PLC and PLD 
Purinergic receptors are known to couple to PI-PLC and 
activate PKC which in turn stimulates PLD in a number of 
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Fig. 5. Competitive inhibition of [35S]ATPTS binding by purinergic 
ligands. Binding of [35S]ATPTS to plasma membranes in the presence of 
increasing concentrations of (A) ATP (O), AMP-CPP (0) and AMP-PCP 
('7); and (B) ATPyS (O), UTP (E]), and ADP ('¢). 
systems [5,17,18,37]. To test whether activation of mem- 
brane-associated PKC could mediate PLD activity we uti- 
lized PMA, an activator of PKC, and bisindolylmaleimide, 
an inhibitor of PKC. PMA did not stimulate PEth forma- 
tion (data not shown). Furthermore, bisindolylmaleimide 
had no effect on agonist-or GTPTS-stimulated PLD activ- 
ity (data not shown). 
To assess whether G proteins linked to PI-PLC, such as 
Table 1 
Concentration of ligand which half-maximally inhibits [35S]ATP'yS 
binding to rat liver plasma membrane 
Ligand IC5o (/xM) 
High affinity Low affinity 
ATPyS 0.1 (77) 13 (23) 
ATP 0.6 (65) 900 (35) 
AMP-CPP 5.9 - 
UTP 6.1 - 
AMP-PCP 14.6 (27) 1300 (73) 
ADP 15.8 - 
Adenosine )3000 - 
The binding of 1 nM [35S]ATPyS to membranes was competitively 
inhibited by increasing concentrations of the indicated ligand. Binding 
competition curves were constructed and best fitted to either a one-or 
two-site model, as indicated, using non-linear competitive curve-fitting in
GraphPad InPlot. The numbers in parentheses are the percentages of
high-and low-affinity sites for these ligands which show two sites. 
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Fig. 6. Release of inositol phosphates from myo[3H]inositol-labeled 
plasma membranes. Rats were injected with myo[3H]inositol, and plasma 
membranes were isolated as described in Section 2. PLC activity was 
determined in response to AMP-PCP (0 )  and 2MeSATP (0) in the 
presence of 2 /xM GTPyS. 
members of the Gq family, could also activate PLD, we 
characterized the activation of PLC by purinergic agonists. 
Similar profiles of PI-PLC and PLD stimulation by 
purinergic agonists could suggest activation of both en- 
zymes through the same subset of receptors, and imply 
stimulation of PLD by Gq proteins. PLC activity was 
assessed using endogenously myo[3H]inositol-labeled rat 
liver plasma membranes by measuring the release of 
[3H]inositol phosphate induced by AMP-CPP and 
2MeSATP. The order of PLC activation was AMP-CPP 
>> 2MeSATP(Fig. 6). AMP-CPP stimulated PLC activity 
with an ECs0 value of 150 /xM, whereas AMP-PCP had 
little effect (data not shown). 2MeSATP and vasopressin 
stimulated PI-PLC activity to a similar extent, and consis- 
tently had greater activity than AMP-PCP (data not shown). 
A higher, but still submaximal, concentration f GTPyS (2 
/zM) was necessary to detect agonist-stimulated PI-PLC 
activity than to detect PLD activity. Little PI-PLC activity 
was observed with 2 /zM GTPyS or agonist alone (data 
not shown), indicating the requirement for activation of 
both receptor and G protein to stimulate the response in 
this system. 
4. Discuss ion 
ATP mediates a myriad of responses in perfused liver, 
hepatocytes and liver plasma membranes, including release 
of eicosanoids, cAMP accumulation, glycogenolysis, phos- 
pholipid base exchange, and activation of PI-PLC, PC-PLC 
and PC-PLD [38-43]. We previously demonstrated 
purinergic-stimulated release of [3H]choline plus 
phospho[3H]choline from liver plasma membranes i olated 
from rats previously injected with [3H]choline [43]. How- 
ever, this study did not show the relative involvement of 
PC-PLD and PC-PLC. An unequivocal role for PLD was 
later shown by measuring the formation of PEth [3]. The 
present report extends the characterization f a GTPTS- 
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stimulated PLD activity in rat liver plasma membranes 
which is regulated by purinergic agonists. The synergistic 
activation of PLD by GTPyS and purinergic agonists 
indicates the involvement of a receptor-G protein complex. 
A functional interaction between a receptor and G protein 
is further suggested by the increased rate of PEth forma- 
tion and the leftward shift in the dose-response curve for 
GTPT S in the presence of AMP-PCP. All these changes 
are typically observed for responses mediated by het- 
erotrimeric G proteins (for references, ee Ref. [44]). How- 
ever, activation of PLD activity in liver plasma membranes 
is insensitive to pertussis-and cholera-toxins, indicating 
that Gi, G O or G s are not involved [4]. Another indicator of 
a role for heterotrimeric G proteins, namely activation by 
AIF 4, cannot be applied to this system since F inhibits 
PLD activity per se [4]. 
Several recent reports indicate that small G proteins of 
the ARF and Rho families stimulate PLD activity [30-33]. 
Direct activation of these small G proteins by membrane 
receptors has not been demonstrated. However, activation 
of Ras occurs after stimulation of seven-transmembrane 
spanning receptors by a poorly understood mechanism, and 
may be downstream of heterotrimeric G protein activation 
via fly subunits [45]. The present study does not address 
the issue of small G proteins. Although it is unlikely that 
they are activated irectly by receptors, the possibility that 
membrane-associated small G proteins mediate the activa- 
tion of PLD by heterotrimeric G proteins, or that multiple, 
independent G protein pathways exist, cannot be dis- 
counted. 
The dose-dependent stimulation of PLD by purinergic 
agonists demonstrates a rank order of efficacy of AMP- 
PCP > ATPyS -- ADP = ATP = 2MeSATP > AMP-CPP 
= UTP. This efficacy order for stimulation of PLD is 
unusual. None of the 'selective' agonists for the known 
purinergic receptors are selective for the PLD response. 
For example, the P2x-selective agonist AMP-CPP is unable 
to stimulate PLD activity, as is the case for the P2v-selec- 
tive agonist UTP. Furthermore, the P2Y agonist 2MeSATP 
is active in stimulating PLD, but AMP-PCP, which does 
not activate P2Y receptors, is the most potent agonist able 
to stimulate PLD. P2z receptors are unlikely to mediate the 
PLD response since ADP is inactive at these receptors, but 
stimulates PLD activity in rat liver plasma membranes to a 
similar extent as ATP. Therefore, a novel purinergic recep- 
tor subtype, or a variant of an identified receptor with 
novel binding properties, appears to be responsible for the 
purinergic-and GTPyS-stimulated PLD activity in rat liver 
plasma membranes. Novel purinergic receptor subtypes 
have been suggested to occur in other tissues based on 
rank potency order of agonists, agonist affinities, and 
differential agonist responses [26,37,46]. 
High concentrations of purinergic agonists were neces- 
sary to elicit PLD and PLC activity, as is often seen by 
other investigators [19,25,27,37,39]. Binding competition 
was performed in the presence of Mg 2÷ to more closely 
correlate to the conditions for assay of PLD, which re- 
quires Mg 2+. Divalent cations may enhance binding of 
purinergic agents to ATPases which sequester or degrade 
ligand [26,47], but decrease affinity for the PLD-linked P2 
receptor [37]. Alternatively, desensitization, degradation or
uncoupling of the purinergic receptors and other compo- 
nents during plasma membranes i olation may occur. 
Stimulation of PI-PLC does not appear to be involved 
in the activation of PLD in isolated rat liver plasma 
membranes. The agonist-dependent release of [3H]inositol 
phosphates differed from PEth formation in agonist po- 
tency, Ca 2+ dependence, and GTPTS requirement. AMP- 
CPP greatly stimulated PLC activity, but had little effect 
on PLD activity. AMP-PCP had the opposite ffects. We 
were unable to demonstrate PI-PLC activity at a low free 
Ca 2+ concentration (200 nM) at which PLD was stimu- 
lated in the presence of agonist (data not shown). In 
contrast, a free Ca 2÷ concentration of 1.3 /zM was re- 
quired to measure PI-PLC activity. Likewise, agonist- 
stimulated PLD responded to 0.2 /zM GTPyS, but 2 /zM 
GTPyS was necessary for PI-PLC activity. However, it 
must be recognized that, in the cell, it is likely that PI-PLC 
plays a role in activation of PLD through the actions of 
PKC. For instance, PMA and Ca 2+ mobilizing agonists 
stimulate PLD activity in hepatocytes, but only purinergic 
agents do so in isolated plasma membranes, and PKC 
downregulation r PKC inhibitors block agonist-stimulated 
PLD activity in several cell systems [5,11,12,17,19]. 
ATP also stimulates PLD and PLC activities in rat 
hepatocytes [4,5,42], but these responses have not been 
fully characterized. ATP and ADP are equipotent in stimu- 
lating PLD in either liver plasma membranes or hepato- 
cytes [4], and ATP and vasopressin have similar potency in 
intact cells [4,5]. However, the doses of ATP and ADP 
necessary to elicit significant PLD activity in isolated 
plasma membranes in this study are greater than those seen 
in intact cells [5]. Purinergic agents also increase PLC 
activity in hepatocytes in the potency order ATPT S > ADP 
= ATP [39], with ECs0 values only slightly less than we 
observed in plasma membranes using AMP-CPP as the 
agonist ( ~ 100/zM vs. 150 /zM). Therefore, disruption of 
hepatocytes and isolation of plasma membranes appears to 
reduce the sensitivity of PLD to purinergic activation, but 
this is not the case for PLC. 
Competition of [3sS]ATPyS binding to plasma mem- 
branes by the agents tested correlates more closely to 
activation of PI-PLC than to activation of PLD. For in- 
stance, AMP-CPP displaced [35S]ATPTS binding and 
stimulated PLC more effectively than AMP-PCP. How- 
ever, AMP-PCP most potently stimulated PLD, yet dis- 
placed [35S]ATP~/S binding poorly. The P2 receptor sub- 
type involved in PLD activation may be rare compared to 
the subtype(s) which regulates PI-PLC. Alternatively, the 
presence of GTPyS in the enzymatic assays may alter the 
receptor affinity to favor AMP-PCP-stimulated PLD activ- 
ity. It should be noted that ATPyS will bind proteins in 
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plasma membranes that are not involved in activation of 
PLD or PLC, thus making correlations between binding 
and receptor activation difficult. 
The use of inhibitors further demonstrates that PLD is 
activated in rat liver plasma membranes by GTPTS and 
agonist in a manner which is independent of PLC activity. 
Bisindolylmaleimide, an inhibitor of the ATP binding site 
of PKC, had no effect on GTPTS-or agonist-and-GTPyS- 
stimulated PLD activity, indicating that active PKC is not 
necessary for activation of PLD in the membranes. How- 
ever, PKC may activate PLD in a phosphorylation- 
independent manner [30], although PMA, an activator of 
PKC, did not enhance PLD activity 2 
This study characterizes the phospholipase r sponses to 
purinergic agonists in rat liver plasma membranes and 
indicates the activation of PLD by these agents. The data 
implicate distinct receptor systems for activation of PLD 
and PI-PLC, and suggest that a receptor for ATP mediates 
PLD activity. The two responses, as detected by formation 
of products from endogenous ubstrates, differ in rank 
order of potency of purinergic agonists, and in their GTP3, S 
and Ca 2+ requirements, implying the involvement of dif- 
ferent receptors and G proteins. However, the exact nature 
of the G-protein involved in the PLD activation pathway 
remains to be determined. 
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